NHLBI Pooled Cohorts Study
Learn more about the NHLBI Pooled Cohorts Study
![](https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_200_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=uKXHTL0O 200w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_260_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=2IGiayiJ 260w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_320_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=JzQLC6Mi 320w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_400_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=1ACyw-yW 400w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_520_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=VkB9HvLW 520w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_640_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=9xqThhu5 640w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_800_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=yjUkfehz 800w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_1040_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=zyOpxFAz 1040w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_1280_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=Ci8nb8g_ 1280w, https://www.genmed.columbia.edu/sites/default/files/styles/cola_media_1600_16_9/public/media/images/2018-10/20180914-0464.jpg?itok=3szERPbZ 1600w)
The NHLBI Pooled Cohorts Study (columbiamedicine.org/pcs; NIH/NHLBI R21-HL121457, R21-HL129924, K23-HL130627): This large, US general population-based sample was developed by systematically harmonizing and pooling data from nine NIH-funded cohorts. Major respiratory outcomes in the NHLBI Pooled Cohorts Study include lung function as well as clinical respiratory events. This resource is allowing us to test for indices and determinants of personalized risk for chronic lung disease in >65,000 US adults with >400,000 person-years of follow-up, as well as providing the phenotypic data for NHLBI’s precision medicine initiative, the Trans-Omics for Precision Medicine (TOPMed) Program.